Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2011-03-01
2011-03-01
Salimi, Ali R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C435S069100
Reexamination Certificate
active
07897155
ABSTRACT:
Mosaic VLPs of viral capsid proteins from different virus types are described, as are methods of making the same. Specifically, a diploid yeast strain that coexpresses the L1 and L2 capsid proteins of both HPV-6 and HPV-16 as mosaic VLPs is described. The mosaic VLPs induced the production of conformational antibodies against both L1 proteins upon administration to mice.
REFERENCES:
patent: 5855891 (1999-01-01), Lowy et al.
patent: 7112330 (2006-09-01), Buonamassa et al.
patent: 7494787 (2009-02-01), Buonamassa et al.
patent: WO 96/05293 (1996-02-01), None
patent: WO 98/14564 (1998-04-01), None
Bonnez, et al., “Propagation Of Human Papillomavirus Type 11 in Human Xenografts Using The Severe Combined Immunodeficiency (SCID) Mouse And Comparison To The Nude Mouse Model,”Virology197:455-458 (1993).
Bonnez, et al., “Isolation And Propagation Of Human Papillomavirus Type 16 in Human Xenografts Implanted In The Sever Combined Immunodeficiency Mouse,”Virol72(6):5256-5261 (1998).
Buonamassa, et al., “Expression Of HPV 6 And 16 Capsid Proteins In Yeast And Induction Of Specific IGA Response In Mice,”Virus Res47(2):126 (1997).
Chan, et al., “Phylogenetic Analysis Of 48 Papillomavirus Types And 28 Subtypes And Variants: A Showcase For The Molecular Evolution Of DNA Viruses,”J Virol66(10):5714-5725 (1992).
Chang, et al., “Phenotypic Mixing Between Different Hepadnavirus Nucleocapsid Proteins Reveals C Protein Dimerization To Be Cis Preferential,”J Virol68(8):5225-5231 (1994).
Christensen, et al., “Antibody-Mediated Neutralization In Vivo Of Infectios Papillomaviruses,”J Virol64(7):3151-3156 (1990).
Christensen, et al., “Monoclonal Antibody-Mediated Neutralization Of Infectious Human Papillomavirus Type 11,”J Virol64(11):5678-5681 (1990).
Christensen, et al., “Human Papillomavirus Types 6 And 11 Have Antigenically Distinct Strongly Immunogenic Conformationally Dependent Neutralizing Epitopes,”Virology205:329-335 (1994).
Christensen, et al., “Monoclonal Antibodies To HPV-6 L1 Virus-Like Particles Identify Conformational And Linear Neutralizing Epitopes On HPV-11 In Addition To Type-Specific Epitopes On HPV-6,”Virology224:477-486 (1996).
Christensen, et al., “Surface Conformational And Linear Epitopes On HPV-16 And HPV-18 L1 Virus-Like Particles As Defined By Monoclonal Antibodies,”Virology223:174-184 (1996).
Deminie, et al., “Incorporation Of Human Immunodeficiency Virus Type 1 Gag Proteins Into Murine Leukemia Virus Virions,”J Virol67(11):6499-6506 (1993).
Doorbar, et al., “Identification Of Proteins Encoded By The L1 And L2 Open Reading Frames Of Human Papillomavirus 1a,”J Virol61(9):2793-2799 (1987).
Firzlaff, et al., “Detection Of Human Papillomavirus Capsid Antigens In Various Squamous Epithelial Lesions Using Antibodies Directed Against The L1 and L2 Open Reading Frames,”Virology167:467-477 (1988).
Franke, et al., “Specificity and Sequence Requirements For Interactions Between Various Retroviral Gag Proteins,”J Virol68(8):5300-5305 (1994).
Greer, et al., “Human Papillomavirus (HPV) Type Distribution And Serological Response To HPV Type 6 Virus-Like Particles In Patients With Genital Warts,”J Clin Microbiol33(8):2058-2063 (1995).
Hagensee, et al., “Self-Assembly Of Human Papillomavirus Type 1 Capsids By Expression Of The L1 Protein Alone Or By Coexpression Of The L1 and L2 Capsid Proteins,”J Virol67(1):315-322 (1993).
Hagensee, et al., “Three-Dimensional Structure Of Vaccinia Virus-Produced Human Papillomavirus Type 1 Capsids,”J Virol68(7):4503-4505 (1994).
Hines, et al., “The Expression And Processing Of Human Beta-Amyloid Peptide Precursors InSaccharomyces cerevisiae: Evidence For a Novel Endopeptidase In The Yeast Secretory System,”Cell Mol Biol Res40(4):273-284 (1994).
Hofmann, et al., “Sequence Determination Of Human Papillomavirus Type 6a And Assembly Of Virus-Like Particles InSaccharomyces cerevisiae,” Virology209:506-518 (1995).
Hofmann, et al., “Sequence Conservation Within The Major Capsid Protein Of Human Papillomavirus (HPV) Type 18 And Formation Of HPV-18 Virus-Like Particles InSaccharomyces cerevisiae,” J Gen Virol77:465-468 (1996).
Jansen, et al., “Vaccination With Yeast-Expressed Cottontail Rabbit Papillomavirus (CRPV) Virus-Like Particles Protects Rabbits From CRPV-Induced Papilloma Formation,”Vaccine13(16):1509-1514 (1995).
Kirnbauer, et al., “Papillomavirus L1 Major Capsid Protein Self-Assembles Into Virus-Like Particles That Are Highly Immunogenic,”PNAS USA89:12180-12184 (1992).
Kirnbauer, et al., “Efficient Self-Assembly Of Human Papillomavirus Type 16 L1 And L1-L2 Into Virus-Like Particles,”J Virol67(12):6929-6936 (1993).
Kirnbauer, et al., “Virus-Like Particles Of Bovine Papillomavirus Type 4 In Prophylactic And Therapeutic Immunization,”Virology219:37-44 (1996).
Kreider, et al., “Laboratory Production In Vivo Of Infectious Human Papillomavirus Type 11,”J Virol61(2):590-593 (1987).
Li, et al., “Expression Of The Human Papillomavirus Type 11 L1 Capsid Protein InEscherichia coli: Characterization Of Protein Domains Involved In DNA Binding And Capsid Assembly,”J Virol71(4):2988-2995 (1997).
Li, et al., “Intercapsomeric Disulfide Bonds In Papillomavirus Assembly And Disassembly,”J Virol72(3):2160-2167 (1998).
Lowe, et al., “Human Papillomavirus Type 11 (HPV-11) Neutralizing Antibodies In The Serum And Genital Mucosal Secretions Of African Green Monkeys Immunized With HPV-11 Virus-Like Particles Expressed In Yeast,”J Infect Dis176:1141-1145(1997).
Muller, et al., “Papillomavirus Capsid Binding And Uptake By Cells From Different Tissues And Species,” 69(2):948-954 (1995).
Neeper, et al., “Expression Of The Major Capsid Protein Of Human Papillomavirus Type 11 inSaccharomyces cerevisae,” Gene180:1-6 (1996).
Notice Of Opposition To a European Patent No. EP 1105495, “Method For Producing Yeast Expressed HOV Types 6 And 16 Capsid Proteins,” Chiron Corporation, EPA Form 2300.1 04.93 Total Pages: 7.
Ott, et al., “Design And Evlauation Of a Safe And Potent Asjuvant For Human Vaccines,” M.F. Powell and M.J. Newman (eds.),Vaccine Design., The Subunit And Adjuvant Approach, Plenum Press, New York, N.Y., pp. 277-296 (1995).
Qi, et al., “Epithelial Cells Display Separate Receptors For Papillomavirus Vlps And For Soluble L1 Capsid Protein,”Virology216:35-45 (1996).
Roden, et al., “Neutralization Of Bovine Papillomavirus By Antibodies To L1 and L2 Capsid Proteins,”J Virol68(11):7570-7574 (1994).
Roden, et al., “Interaction Of Papillomaviruses With The Cell Surface,”J Virol68(11):7260-7266 (1994).
Roden, et al., “In Vitro Generation And Type-Specific Neutralization Of A Human Papillomavirus Type 16 Virion Pseudotype,”J Virol70(9):5875-5883 (1996).
Roden, et al., “Assessment Of The Serological Relatedness Of Genital Human Papillomaviruses By Hemagglutination Inhibition,”J Virol70(5):3298-3301 (1996).
Rose, et al., “Serological Differentiation Of Human Papillomavirus Types 11, 16 And 18 Using Recombinant Virus-Like Particles,”J Gen Virol75:2445-2449 (1994).
Rose, et al., “Expression Of Human Papillomavirus Type 11 L1 Protein In Insect Cells: In Vivo And In Vitro Assembly Of Viruslike Particles,”J Virol67(4):1936-1944 (1993).
Sapp, et al., “Organization Of The Major And Minor Capsid Proteins In Human Papillomavirus Type 33 Virus-Like Particles,”J Gen Virol76:2407-2412 (1995).
Sapp, et al., “Papillomavirus Assembly Requires Trimerization Of The Major Capsid Protein By Disulfides Between Two Highly Conserved Cysteines,”J Virol72(7):6186-6189 (1998).
Sasagawa, et al., “Synthesis And Assembly Of Virus-Like Particles Of H
Bensi Giuliano
Buonamassa Daniela Tornese
Galeotti Cesira L.
Greer Catherine E.
Petracca Roberto
Bautista Regina
Novartis Vaccines & Diagnostics, Inc.
Salimi Ali R.
LandOfFree
Method for producing yeast expressed HPV types 6 and 16... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for producing yeast expressed HPV types 6 and 16..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for producing yeast expressed HPV types 6 and 16... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2654952